CDK9 and ovarian carcinoma: In agreement with these observations and previous findings with other CDK9 inhibitors [12]–[14], dinaciclib caused a rapid decrease in MCL1 mRNA levels within the first 2 hr of treatment that plateaued at 4–5 hr in the A2780 ovarian cancer cell line (Figure 2C).